ClinicalTrials.gg
CompletedNCT04003389Skylight 4Updated Nov 5, 2024Results posted

A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

A Phase 3 interventional study of fezolinetant and placebo in Hot Flashes, sponsored by Astellas Pharma Global Development, Inc.. Completed at 182 sites in 8 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,831
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.

Enrollment
Largest of 16
1,831 · median 249
Started
2019
with 2 others
Phase 3
10 of 16
2 open now
Registered
2nd of 16
by date
Lead sponsor
6 of 16
Astellas Pharma Global Development, Inc.

Among the 16 studies testing fezolinetant in Hot Flashes, this one has the largest enrollment, is one of 3 that started in 2019, is one of 10 in phase 3, and was the 2nd registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fezolinetant

fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing fezolinetant in Hot Flashes, or all of them as a file.
02

Study summary

This study was for women in menopause with hot flashes. Menopause, a normal part of aging, was the time of a woman's last period. Hot flashes can interrupt a woman's daily life.

The purpose of this study was to find out how safe it is for these women to take fezolinetant in long term (up to 52 weeks). To do that, the study looked at the number and severity of the "adverse events." Those were the side effects that study participants had while they were in the study.

The study treatments were fezolinetant 30 milligrams (mg) (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo was a dummy treatment that looked like medicine but did not have any medicine in it.) Women in this study were picked for 1 of the 3 study treatments by chance alone. The study participants took study treatment for 52 weeks.

This study was "double-blinded." That means that the study participants and the study doctors did not know who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo).

At weeks 2 and 4 and then once a month, the study participants went to the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine were collected for laboratory tests. At some study visits, study participants completed questionnaires that were about their quality of life. At the first and last study visits, they had a dual-energy x-ray absorptiometry (DXA for short) test done. To measure bone loss in the hips and spine, DXA created pictures of the inside of these areas with low-dose x-rays. (The dose was approximately one-tenth of the amount of a normal chest x-ray.) Study participants who still had their uterus had 2 more tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involved removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test was transvaginal ultrasound. It used sound waves to create pictures of the organs in the pelvis. The sound waves were transmitted by a probe (transducer), which was placed inside the vagina. Study participants might have had a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not had this test done in the last 12 months had it done at the first study visit. They had done at the last study visit if they were due for their screening mammogram and their own doctor agreed.

The last check-up at the hospital or clinic was at 3 weeks after the last dose of study treatment.

Read the detailed description

This study consisted of a screening period and a 52 week treatment period. Safety follow up occurred 3 weeks after the last dose of study drug.

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • menopause
  • fezolinetant
  • ESN364
  • vasomotor symptoms
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a ≥ 18 kg/m\^2 and ≤ 38 kg/m\^2.
  • Subject must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and confirmed as menopausal per 1 of the following criteria at the screening visit:

    • Spontaneous amenorrhea for ≥ 12 consecutive months
    • Spontaneous amenorrhea for ≥ 6 months with biochemical criteria of menopause (follicle stimulating hormone > 40 IU/L), or
    • Having had bilateral oophorectomy ≥ 6 weeks prior to the screening visit.
  • Subject is seeking treatment for relief for VMS associated with menopause.
  • Subject is in good general health as determined on the basis of medical history and general physical examination, including a bimanual clinical pelvic examination and clinical breast examination devoid of relevant clinical findings, performed at the screening visit; hematology and biochemistry parameters; pulse rate and/or blood pressure; and within the reference range for the population studied, or showing no deviations.
  • Subject has documentation of a normal/negative or no clinically significant mammogram findings (obtained at screening or within the prior 12 months of study enrollment). Appropriate documentation includes a written report or an electronic report indicating normal/negative or no clinically significant mammographic findings.
  • Subject is willing to undergo a transvaginal ultrasound (TVU) to evaluate the uterus and ovaries at screening and at week 52 end of treatment (EOT). For subjects who are withdrawn from the study prior to completion, a TVU should be collected at the early discontinuation (ED) visit.
  • Subject is willing to undergo an endometrial at screening and at week 52 (EOT) or the ED visit for subjects who are withdrawn from the study prior to completion, and any time during the study in the case of uterine bleeding. The endometrial biopsy obtained at screening must be considered evaluable.
  • Subject has documentation of a normal or not clinically significant Papanicolaou (Pap) test (or equivalent cervical cytology) within the previous 12 months or at screening.
  • Subject has a negative urine pregnancy test at screening.
  • Subject has a negative serology panel (i.e., negative surface antigen, negative virus antibody and negative antibody screens) at screening.
  • Subject agrees not to participate in another interventional study while participating in the present study.

Exclusion criteria

Exclusion Criteria:

  • Subject uses a prohibited therapy (strong or moderate cytochrome P450 [CYP] 1A2 inhibitors, hormone replacement therapy [HRT], hormonal , any treatment for VMS [prescription, over the counter or herbal]) or is not willing to wash out and discontinue such drugs for the full extent of the study.
  • Subject has a known substance abuse or alcohol addiction within 6 months of screening.
  • Subject has previous or current history of a malignant tumor, except for basal cell carcinoma.
  • Subject's systolic blood pressure is ≥ 130 mmHg or diastolic blood pressure is ≥ 80 mmHg based on the average of 2 to 3 readings, on at least 2 different occasions within the screening period.

    • Subjects who do not meet these criteria may be re-assessed after initiation or review of antihypertensive measures.
    • Subjects with a medical history of hypertension can be enrolled once they are medically clear (stable and compliant).
  • Subject has a history of severe allergy, or intolerance to drugs in general, including the study drug and any of its .
  • Subject has an unacceptable result from the TVU assessment at screening, i.e., full length of endometrial cavity cannot be visualized or presence of a finding.
  • Subject has an endometrial confirming presence of disordered proliferative endometrium, endometrial hyperplasia, endometrial cancer, or other clinically significant findings at screening.
  • Subject has a history within the last 6 months of undiagnosed uterine bleeding.
  • Subject has a history of seizures or other convulsive disorders.
  • Subject has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine or gynecological disease) or that could confound interpretation of the study outcome.
  • Subject has active liver disease, jaundice or elevated liver aminotransferases ( [ALT] or aspartate aminotransferase [AST]), elevated total or direct , elevated (INR), or elevated alkaline phosphatase (ALP). Patients with mildly elevated ALT or AST up to 1.5 times the (ULN) can be enrolled if total and direct bilirubin are normal. Patients with mildly elevated ALP (up to 1.5 x ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Patients with Gilbert's syndrome with elevated total bilirubin may be enrolled as long as direct bilirubin, and reticulocytes are normal.
  • Subject has creatinine > 1.5 x ULN; or estimated using the Modification of Diet in Renal Disease formula ≤ 59 mL/min per 1.73 m\^2 at the screening visit.
  • Subject has a history of suicide attempt or suicidal behavior within the last 12 months or has suicidal ideation within the last 12 months (a response of "yes" to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale [C-SSRS]), or who is at significant risk to commit suicide, as assessed at screening and at the time of visit 2 (randomization).
  • Subject has previously been enrolled in a clinical trial with fezolinetant.
  • Subject is participating concurrently in another interventional study or participated in an interventional study within 28 days prior to screening, or received any drug within 28 days or within 5 half-lives prior to screening, whichever is longer.
  • Subject is unable or unwilling to complete the study procedures.
  • Subject has any condition which makes the subject unsuitable for study participation.
  • Subject has had a partial or full hysterectomy.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,831 participants (actual)

Study arms

  • Experimental
    Fezolinetant 30 mg

    Participants received fezolinetant 30 mg (one 30 mg fezolinetant tablet and one placebo tablet) orally, once daily (QD) for a period of 52 Weeks.

    Drug: fezolinetant

  • Experimental
    Fezolinetant 45 mg

    Participants received fezolinetant 45 mg (one 30 mg tablet and one 15 mg tablet) orally, QD for a period of 52 Weeks.

    Drug: fezolinetant

  • Placebo comparator
    Placebo

    Participants received fezolinetant matching placebo (two fezolinetant matching placebo tablets) orally, QD for a of period of 52 Weeks.

    Drug: placebo

Interventions

  • administered orally

  • Drugplacebo

    administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a participant administered a study drug, \& which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable \& unintended sign, symptom, or disease temporally associated with the use of medicinal product (MP) whether or not considered related to MP. An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. A TEAE is defined as an AE observed after starting administration of study drug \& 21 days after the last dose of study drug.

    Time frame: From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks)

  2. Number of Participants With Mild, Moderate and Severe TEAE

    An adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. A TEAE is defined as an AE observed after starting administration of the study drug and 21 days after the last dose of study drug. Severity of AE we were classified as Mild: No disruption of normal daily activities; Moderate: Affect normal daily activities; and Severe: Inability to perform daily activities.

    Time frame: From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks)

  3. Percentage of Participants With Endometrial Hyperplasia

    Endometrial hyperplasia was confirmed from the endometrial biopsy report.

    Time frame: Baseline Up to 52 weeks

  4. Percentage of Participants With Endometrial Cancer

    Endometrial cancer was confirmed from the endometrial biopsy report.

    Time frame: Baseline Up to 52 weeks

Secondary outcomes

  1. Change From Baseline in Endometrial Thickness at Week 52

    Endometrial thicness was obtained from the transvaginal ultrasound. The endometrium was measured in the long axis or sagittal plane. The measurement was of the thickest echogenic area from 1 basal endometrial interface across the endometrial canal to the other basal surface.

    Time frame: Baseline and week 52

  2. Percentage of Participants With Disordered Proliferative Endometrium

    Disordered proliferative endometrium was confirmed from the endometrial biopsy report.

    Time frame: Baseline Up to 52 weeks

  3. Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52

    Changes in BMD hip was assessed by dual-energy X-ray absorptiometry (DXA) scan.

    Time frame: Baseline and week 52

  4. Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52

    TBS was a bone texture assessment that serves as a substitute for bone microarchitecture and predicts fracture risk independent of BMD and clinical risk factors. The DXA imaging was processed and analyzed as it would normally be and then evaluated using an automated algorithm to determine the TBS. T-score ≥1.350 was considered to be normal; T-score between 1.200 and 1.350 is considered to be consistent with partially degraded microarchitecture; and T-score ≤1.200 defines degraded microarchitecture.

    Time frame: Baseline and week 52

  5. Change From Baseline in BMD at Spine at Week 52

    Changes in BMD spine was assessed by DXA scan.

    Time frame: Baseline and week 52

  6. Change From Baseline in TBS at Spine at Week 52

    TBS was a bone texture assessment that serves as a substitute for bone microarchitecture and predicts fracture risk independent of BMD and clinical risk factors. The DXA imaging was processed and analyzed as it would normally be and then evaluated using an automated algorithm to determine the TBS. T-score ≥1.350 was considered to be normal; T-score between 1.200 and 1.350 is considered to be consistent with partially degraded microarchitecture; and T-score ≤1.200 defines degraded microarchitecture.

    Time frame: Baseline and week 52

  7. Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS assessed the risk for suicidal behavior and suicide ideation. Participants responded as "Yes" or "No" 10 items. Suicidal ideation (1. Wish to be dead; 2. Non-specific active suicidal thoughts; 3. Active suicidal ideation with any methods (not plan) without intent to act; 4. Active suicidal ideation with some intent to act, without specific plan; 5. Active suicidal ideation with specific plan and intent; ). Suicidal behaviour (1. Preparatory acts or behavior 2. Aborted attempt 3. Interrupted attempt 4. Actual attempt 5. Completed suicide). Participants with 'Yes' to any one of the above 10 questions for suicidal ideation and behavior were reported.

    Time frame: Baseline, week 12, week 24, week 52 and follow-up (week 55)

  8. Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS

    The C-SSRS assessed the risk for Self-injurious Behavior without Suicidal Intent. Question was asked "Has participant engaged in Non-Suicidal Self-Injurious Behavior?". Participants with 'yes' to the question were reported.

    Time frame: Baseline, week 12, week 24, week 52 and follow-up (week 55)

07

Results

Posted Feb 1, 2023

Participant flow

Female participants aged ≥ 40 and ≤ 65 years seeking treatment for vasomotor symptoms (VMS) associated with menopause and who met the inclusion criteria and none of the exclusion criteria were enrolled in this study.

Participant flow — Overall Study
MilestonePlaceboFezolinetant 30 mgFezolinetant 45 mg
Started611611609
Treated610611609
Completed410451444
Not completed201160165
Withdrew: Adverse event273428
Withdrew: Lost to follow-up393033
Withdrew: Protocol violation165
Withdrew: Withdrawal by subject1197985
Withdrew: Miscellaneous141114
Withdrew: Participant did not receive study drug100

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a participant administered a study drug, \& which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable \& unintended sign, symptom, or disease temporally associated with the use of medicinal product (MP) whether or not considered related to MP. An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. A TEAE is defined as an AE observed after starting administration of study drug \& 21 days after the last dose of study drug.

Time frame:
From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
participantsPlaceboFezolinetant 30 mgFezolinetant 45 mg
TEAE391415389
Drug-Related TEAE10694110
Serious TEAE142023
Drug-Related Serious TEAE100
TEAE Leading to Death010
Drug-Related TEAE Leading to Death000
TEAE Leading to Withdrawal of Treatment263428
Drug-Related TEAE Leading to Withdrawal of Treatment161617
Death010
PrimaryNumber of Participants With Mild, Moderate and Severe TEAE

An adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. A TEAE is defined as an AE observed after starting administration of the study drug and 21 days after the last dose of study drug. Severity of AE we were classified as Mild: No disruption of normal daily activities; Moderate: Affect normal daily activities; and Severe: Inability to perform daily activities.

Time frame:
From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks)
Reported as:
Number · participants
Number of Participants With Mild, Moderate and Severe TEAE
participantsPlaceboFezolinetant 30 mgFezolinetant 45 mg
Mild180215195
Moderate191185171
Severe201523
PrimaryPercentage of Participants With Endometrial Hyperplasia

Endometrial hyperplasia was confirmed from the endometrial biopsy report.

Time frame:
Baseline Up to 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Endometrial Hyperplasia
percentage of participantsPlaceboFezolinetant 30 mgFezolinetant 45 mg
Percentage of Participants With Endometrial Hyperplasia000.5
PrimaryPercentage of Participants With Endometrial Cancer

Endometrial cancer was confirmed from the endometrial biopsy report.

Time frame:
Baseline Up to 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Endometrial Cancer
percentage of participantsPlaceboFezolinetant 30 mgFezolinetant 45 mg
Percentage of Participants With Endometrial Cancer00.50
SecondaryChange From Baseline in Endometrial Thickness at Week 52

Endometrial thicness was obtained from the transvaginal ultrasound. The endometrium was measured in the long axis or sagittal plane. The measurement was of the thickest echogenic area from 1 basal endometrial interface across the endometrial canal to the other basal surface.

Time frame:
Baseline and week 52
Reported as:
Mean · millimeter (mm)
Change From Baseline in Endometrial Thickness at Week 52
millimeter (mm)PlaceboFezolinetant 30 mgFezolinetant 45 mg
Change From Baseline in Endometrial Thickness at Week 52-0.17 ± 2.35-0.15 ± 1.97-0.28 ± 2.30
Statistical analysis
  • Placebo vs Fezolinetant 30 mg · ANCOVA · p = 0.0604 (LSM, SE, CI, \& p-values come from an analysis of covariance (ANCOVA) model with change from baseline at Week 52 timepoint as response, treatment \& smoking status (current vs former/never) as fixed effects with baseline weight \& baseline as covariate.) · Lsmean difference: -0.08 · 95% CI -0.36 to 0.21
  • Placebo vs Fezolinetant 45 mg · ANCOVA · p = 0.239 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: -0.17 · 95% CI -0.45 to 0.11
SecondaryPercentage of Participants With Disordered Proliferative Endometrium

Disordered proliferative endometrium was confirmed from the endometrial biopsy report.

Time frame:
Baseline Up to 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Disordered Proliferative Endometrium
percentage of participantsPlaceboFezolinetant 30 mgFezolinetant 45 mg
Percentage of Participants With Disordered Proliferative Endometrium2.21.40
SecondaryChange From Baseline in Bone Mineral Density (BMD) at Hip at Week 52

Changes in BMD hip was assessed by dual-energy X-ray absorptiometry (DXA) scan.

Time frame:
Baseline and week 52
Reported as:
Mean · gram per square centimeter (g/cm^2)
Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52
gram per square centimeter (g/cm^2)PlaceboFezolinetant 30 mgFezolinetant 45 mg
Hip (Femoral Neck)-0.010 ± 0.033-0.001 ± 0.044-0.009 ± 0.033
Hip (Femur)-0.011 ± 0.022-0.003 ± 0.041-0.008 ± 0.024
Hip (Trochanter)-0.008 ± 0.027-0.001 ± 0.042-0.004 ± 0.026
Statistical analysis
  • Placebo vs Fezolinetant 30 mg · ANCOVA · p = 0.029 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.007 · 95% CI 0.001 to 0.014
  • Placebo vs Fezolinetant 45 mg · ANCOVA · p = 0.867 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.001 · 95% CI -0.006 to 0.007
  • Placebo vs Fezolinetant 30 mg · ANCOVA · p = 0.027 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.006 · 95% CI 0.001 to 0.012
  • Placebo vs Fezolinetant 45 mg · ANCOVA · p = 0.410 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.002 · 95% CI -0.003 to 0.008
  • Placebo vs Fezolinetant 30 mg · ANCOVA · p = 0.087 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.005 · 95% CI -0.001 to 0.011
  • Placebo vs Fezolinetant 45 mg · ANCOVA · p = 0.259 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.003 · 95% CI -0.002 to 0.009
SecondaryChange From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52

TBS was a bone texture assessment that serves as a substitute for bone microarchitecture and predicts fracture risk independent of BMD and clinical risk factors. The DXA imaging was processed and analyzed as it would normally be and then evaluated using an automated algorithm to determine the TBS. T-score ≥1.350 was considered to be normal; T-score between 1.200 and 1.350 is considered to be consistent with partially degraded microarchitecture; and T-score ≤1.200 defines degraded microarchitecture.

Time frame:
Baseline and week 52
Reported as:
Mean · T-Score (Index)
Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52
T-Score (Index)PlaceboFezolinetant 30 mgFezolinetant 45 mg
Hip (Femoral Neck)-0.078 ± 0.246-0.011 ± 0.372-0.073 ± 0.265
Hip (Femur)-0.085 ± 0.192-0.024 ± 0.354-0.063 ± 0.192
Hip (Trochanter)-0.071 ± 0.255-0.009 ± 0.426-0.036 ± 0.246
Statistical analysis
  • Placebo vs Fezolinetant 30 mg · ANCOVA · p = 0.079 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.048 · 95% CI -0.006 to 0.102
  • Placebo vs Fezolinetant 45 mg · ANCOVA · p = 0.980 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.001 · 95% CI -0.052 to 0.053
  • Placebo vs Fezolinetant 30 mg · ANCOVA · p = 0.042 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.048 · 95% CI 0.002 to 0.094
  • Placebo vs Fezolinetant 45 mg · ANCOVA · p = 0.386 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.020 · 95% CI -0.025 to 0.065
  • Placebo vs Fezolinetant 30 mg · ANCOVA · p = 0.156 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.041 · 95% CI -0.016 to 0.099
  • Placebo vs Fezolinetant 45 mg · ANCOVA · p = 0.328 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.028 · 95% CI -0.028 to 0.084
SecondaryChange From Baseline in BMD at Spine at Week 52

Changes in BMD spine was assessed by DXA scan.

Time frame:
Baseline and week 52
Reported as:
Mean · g/cm^2
Change From Baseline in BMD at Spine at Week 52
g/cm^2PlaceboFezolinetant 30 mgFezolinetant 45 mg
Change From Baseline in BMD at Spine at Week 52-0.013 ± 0.035-0.010 ± 0.049-0.014 ± 0.034
Statistical analysis
  • Placebo vs Fezolinetant 30 mg · ANCOVA · p = 0.497 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.002 · 95% CI -0.005 to 0.009
  • Placebo vs Fezolinetant 45 mg · ANCOVA · p = 0.878 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: -0.001 · 95% CI -0.007 to 0.006
SecondaryChange From Baseline in TBS at Spine at Week 52

TBS was a bone texture assessment that serves as a substitute for bone microarchitecture and predicts fracture risk independent of BMD and clinical risk factors. The DXA imaging was processed and analyzed as it would normally be and then evaluated using an automated algorithm to determine the TBS. T-score ≥1.350 was considered to be normal; T-score between 1.200 and 1.350 is considered to be consistent with partially degraded microarchitecture; and T-score ≤1.200 defines degraded microarchitecture.

Time frame:
Baseline and week 52
Reported as:
Mean · T-Score (Index)
Change From Baseline in TBS at Spine at Week 52
T-Score (Index)PlaceboFezolinetant 30 mgFezolinetant 45 mg
Change From Baseline in TBS at Spine at Week 52-0.117 ± 0.296-0.084 ± 0.025-0.119 ± 0.298
Statistical analysis
  • Placebo vs Fezolinetant 30 mg · ANCOVA · p = 0.527 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: 0.020 · 95% CI -0.042 to 0.082
  • Placebo vs Fezolinetant 45 mg · ANCOVA · p = 0.872 (The LSM, SE, CI, and p-values come from an ANCOVA model with change from baseline at the Week 52 timepoint as response, treatment and smoking status (current vs former/never) as fixed effects with baseline weight and baseline as covariates.) · Lsmean difference: -0.005 · 95% CI -0.066 to 0.056
SecondaryNumber of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

The C-SSRS assessed the risk for suicidal behavior and suicide ideation. Participants responded as "Yes" or "No" 10 items. Suicidal ideation (1. Wish to be dead; 2. Non-specific active suicidal thoughts; 3. Active suicidal ideation with any methods (not plan) without intent to act; 4. Active suicidal ideation with some intent to act, without specific plan; 5. Active suicidal ideation with specific plan and intent; ). Suicidal behaviour (1. Preparatory acts or behavior 2. Aborted attempt 3. Interrupted attempt 4. Actual attempt 5. Completed suicide). Participants with 'Yes' to any one of the above 10 questions for suicidal ideation and behavior were reported.

Time frame:
Baseline, week 12, week 24, week 52 and follow-up (week 55)
Reported as:
Number · participants
Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
participantsPlaceboFezolinetant 30 mgFezolinetant 45 mg
Baseline224
Week 12001
Week 24112
Week 52100
Follow-up (Week 55)012
SecondaryNumber of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS

The C-SSRS assessed the risk for Self-injurious Behavior without Suicidal Intent. Question was asked "Has participant engaged in Non-Suicidal Self-Injurious Behavior?". Participants with 'yes' to the question were reported.

Time frame:
Baseline, week 12, week 24, week 52 and follow-up (week 55)
Reported as:
Number · participants
Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS
participantsPlaceboFezolinetant 30 mgFezolinetant 45 mg
Baseline010
Week 12100
Week 24000
Week 52000
Follow-up (Week 55)100

Adverse events

Collected over From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/610 (0%)14/610 (2.3%)90/610 (14.8%)
Fezolinetant 30 mg1/611 (0.2%)20/611 (3.3%)86/611 (14.1%)
Fezolinetant 45 mg0/609 (0%)23/609 (3.8%)78/609 (12.8%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventPlaceboFezolinetant 30 mgFezolinetant 45 mg
Abdominal painGastrointestinal disorders0/6101/6112/609
COVID-19Infections and infestations1/6100/6112/609
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/6100/6112/609
Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/6101/6112/609
GoitreEndocrine disorders0/6101/6111/609
PancreatitisGastrointestinal disorders0/6100/6111/609
VomitingGastrointestinal disorders0/6100/6111/609
Chest painGeneral disorders0/6100/6111/609
InfluenzaInfections and infestations1/6100/6111/609
MeningitisInfections and infestations0/6100/6111/609
Most frequent other events
Most frequent other events
EventPlaceboFezolinetant 30 mgFezolinetant 45 mg
HeadacheNervous system disorders56/61052/61154/609
COVID-19Infections and infestations37/61038/61130/609

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(Years)PlaceboFezolinetant 30 mgFezolinetant 45 mgTotal
Mean54.8 ± 4.854.7 ± 4.754.7 ± 4.854.7 ± 4.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFezolinetant 30 mgFezolinetant 45 mgTotal
Female6116116091831
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboFezolinetant 30 mgFezolinetant 45 mgTotal
Hispanic or Latino133118116367
Not Hispanic or Latino4784934911462
Unknown or Not Reported0022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboFezolinetant 30 mgFezolinetant 45 mgTotal
American Indian or Alaska Native3328
Asian881329
Native Hawaiian or Other Pacific Islander0000
Black or African American92114110316
White5024794791460
More than one race66416
Unknown or Not Reported0112
Smoking status
Smoking status(participants)PlaceboFezolinetant 30 mgFezolinetant 45 mgTotal
Current117116116349
Former/Never4944954931482
08

Study locations

182 sites
  • SEC Clinical Research
    Andalusia, Alabama 36420, United States
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35205, United States
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35235, United States
  • Achieve Clinical Research, LLC
    Ensley, Alabama 35218, United States
  • Mesa Obstetricians and Gynecologists
    Mesa, Arizona 85209, United States
  • Medpharmics LLC
    Phoenix, Arizona 85015, United States
  • Precision Trials
    Phoenix, Arizona 85032, United States
  • Del Sol Research Management
    Tucson, Arizona 85712, United States
  • Visions Clinical Research - Tuscon
    Tucson, Arizona 85712, United States
  • Eclipse Clinical Research
    Tucson, Arizona 85745, United States
  • Hope Research Institute
    Canoga Park, California 91303, United States
  • Alliance Research Inc
    Canoga Park, California 91304, United States
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
  • Grossmont Center for Clinical Research
    La Mesa, California 91942, United States
  • Downtown L.A. Research Center, Inc.
    Los Angeles, California 90017, United States
  • National Research Institute - Panorama
    Los Angeles, California 90057, United States
  • Excell Research
    Oceanside, California 92056, United States
  • Clinical Trials Research
    Sacramento, California 95821, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • Wake Research Associates, LLC
    San Diego, California 92108, United States
  • Women's Healthcare Affiliates
    San Diego, California 92111, United States
  • CITrials, Inc
    Santa Ana, California 92705, United States
  • Millennium Clinical Trials
    Thousand Oaks, California 91360, United States
  • Women's Medical Group of Upland
    Upland, California 91786, United States
  • Bayview Research Group
    Valley Village, California 91607, United States
  • Downtown Women's Health Care
    Denver, Colorado 80209, United States
  • Horizons Clincial Research Center LLC
    Denver, Colorado 80220, United States
  • Coastal Connecticut Research, LLC
    New London, Connecticut 06320, United States
  • Emerson Clinical Research institute
    Washington, District of Columbia 20011, United States
  • Olympian Clinical Research
    Clearwater, Florida 33757, United States
  • Precision Clinical Research
    Coral Springs, Florida 33065, United States
  • Nature Coast Clinical Research
    Crystal River, Florida 34429, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Universal Axon Clinical Research
    Doral, Florida 33166, United States
  • Fleming Island Center for Clinical Research
    Fleming Island, Florida 32003, United States
  • Clinical Physiology Associates
    Fort Myers, Florida 33912, United States
  • Florida Medical Research
    Gainesville, Florida 32607, United States
  • Vital Pharma Research Inc.
    Hialeah, Florida 33016, United States
  • Health Awareness
    Jupiter, Florida 33458, United States
  • Multi-Specialty Research Associates, Inc.
    Lake City, Florida 32055, United States
  • Altus Research
    Lake Worth, Florida 33461, United States
  • LCC Medical Research Institute, LLC
    Miami, Florida 33126, United States
  • Medical Research Center of Miami II
    Miami, Florida 33134, United States
  • Medical Research Centers of South Florida, Inc.
    Miami, Florida 33144, United States
  • Florida International Research Center
    Miami, Florida 33174, United States
  • Spotlight research center
    Miami, Florida 33176, United States
  • Med Research Of Florida, LLC
    Miami, Florida 33186, United States
  • New Age Medical Research Corporation
    Miami, Florida 33186, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Healthcare Clinical Data Inc
    North Miami, Florida 33161, United States
  • Sensible Healthcare LLC
    Ocoee, Florida 34761, United States
  • Bioclinica Research
    Orlando, Florida 32806, United States
  • Clinical Neuroscience Solutions, Inc
    Orlando, Florida 32806, United States
  • Omega Research Consultants
    Orlando, Florida 32808, United States
  • Cornerstone Research Institute
    Orlando, Florida 32822, United States
  • Ormond Medical Arts Pharmaceutical Research Center
    Ormond Beach, Florida 32174, United States
  • Sunset Point Medical Associates
    Palm Harbor, Florida 34684, United States
  • Radiant Research
    Pinellas Park, Florida 33781, United States
  • St. Johns Center for Clinical Research
    Ponte Vedra, Florida 32081, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Health Awareness
    Port Saint Lucie, Florida 34952, United States
  • Precision Clinical Research
    Sunrise, Florida 33351, United States
  • GCP Clinical Research, LLC
    Tampa, Florida 33614, United States
  • Premier Medical Associates
    The Villages, Florida 32159, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida 33880, United States
  • Agile Clinical Research Trials, LLC
    Atlanta, Georgia 30328, United States
  • iResearch Atlanta LLC
    Decatur, Georgia 30030, United States
  • NuDirections Clinical Research
    Duluth, Georgia 30096, United States
  • Infinite Clinical Trials
    Riverdale, Georgia 30274, United States
  • WR-Mount Vernon Clinical Research
    Sandy Springs, Georgia 30328, United States
  • Georgia Clinical Research
    Snellville, Georgia 30078, United States
  • Rosemark Women Care Specialists
    Idaho Falls, Idaho 83404, United States
  • The Healing Sanctuary, LLC
    Idaho Falls, Idaho 83404, United States
  • Womens Health USA, Inc.
    Champaign, Illinois 61820, United States
  • Affinity Clinical Research Institute
    Oak Brook, Illinois 60523, United States
  • Investigators Research Group, Llc
    Brownsburg, Indiana 46254, United States
  • MediSphere Medical Research
    Evansville, Indiana 47714, United States
  • Cypress Medical Research Center
    Wichita, Kansas 67226, United States
  • Avant Research Associates, LLC
    Crowley, Louisiana 70526, United States
  • Praetorian Pharmaceutical Research
    Marrero, Louisiana 70072, United States
  • Southern Clinical Research Associates
    Metairie, Louisiana 70001, United States
  • Medpharmics, LLC
    Metairie, Louisiana 70006, United States
  • Pharmasite Research Inc
    Baltimore, Maryland 21208, United States
  • Bay State Clinical Trials, Inc.
    Watertown, Massachusetts 02472, United States
  • Saginaw Valley Medical Research Group, Llc
    Saginaw, Michigan 48604, United States
  • Montana Medical Research Inc
    Missoula, Montana 59801, United States
  • Quality Clinical Research, Inc
    Omaha, Nebraska 68114, United States
  • Clinical Research Center of Nevada (CRCN)
    Las Vegas, Nevada 89104-3218, United States
  • Excel Clinical Research, LLC
    Las Vegas, Nevada 89109, United States
  • Office Of Edmond Pack, Md
    Las Vegas, Nevada 89113, United States
  • Dr.R. Garn Mabey, MD,Office Of
    Las Vegas, Nevada 89128, United States
  • Hassman Research Institute, LLC
    Berlin, New Jersey 08009, United States
  • Lawrence OBGYN Associates
    Lawrenceville, New Jersey 08648, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Bosque Women's Care
    Albuquerque, New Mexico 87109-4640, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Circuit Clinical
    West Seneca, New York 14224, United States
  • Upstate Clinical Research Associates LLC
    Williamsville, New York 14221, United States
  • OnSite Clinical Solutions, LLC
    Charlotte, North Carolina 28277, United States
  • Carolina women's research and wellness center
    Durham, North Carolina 27714, United States

Showing the first 100 of 182 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jan 2022, 29 months.

Results were first posted in Feb 2023, 1 year after primary completion.

Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2019
First posted
Jul 1, 2019
StartActual
Jul 10, 2019
Primary completionActual
Jan 4, 2022
CompletionActual
Jan 4, 2022
Results first posted
Feb 1, 2023
Last update
Nov 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04003389
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
Jul 10, 2019
Primary completion
Jan 4, 2022
Completion
Jan 4, 2022
Results posted
Feb 1, 2023
Last update
Nov 5, 2024

Study contacts

Executive Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion